We examined the effect of maternal smoking on plasma and urinary levels of vitamin E isoforms in preterm infants. Maternal smoking during pregnancy decreased infant plasma alpha-and gamma-tocopherol concentrations at 1 week and 4 weeks, with 45% of infants of smokers deficient in alpha-tocopherol at 1 month after birth. (J Pediatr 2018;197:280-5).
Alpha-CEHC [2,5,7,8-tetramethyl-2-(2'-carboxyethyl)-6-hydroxychroman] and gamma-CEHC [2,7,8-trimethyl-2-(beta-carboxyethyl)-6-hydroxychroman] are the main urinary metabolites of alpha-and gamma-tocopherol, respectively. [15] [16] [17] [18] Maternal smoking has been demonstrated to affect the amount of tocopherols present in umbilical cord blood samples, and is postulated to affect the infant's ability to handle oxidative stress. 19 Measurement of these molecules in neonates has previously required a blood draw for plasma or whole blood, which poses technical and medical challenges in small preterm infants. In this study, we examined the effects of maternal smoking on levels of tocopherols and their urinary metabolites in preterm infants in the first postnatal month. We also sought to determine whether urinary and plasma levels of alpha-and gammatocopherol and their respective metabolites correlate with one another in the first weeks after birth. This is important for both research and clinical purposes, because it would reduce the need for blood draws to measure these molecules, and facilitate multiple, longitudinal assessments of tocopherol metabolites in research studies.
Methods
We studied 41 preterm infants with available blood and urine samples obtained at either 1 week after birth or 1 month after birth to evaluate correlations between plasma alpha-and gamma-tocopherol and their primary urinary metabolites, alpha-and gamma-CEHC. In addition, we analyzed urinary concentrations of F2-isoprostanes, a biomarker of oxidative stress. We had available blood samples at both time points for 30 preterm infants, and urine samples at both time points for 32 infants.
Paired blood and urine samples from the same day were obtained from each infant, although not all infants were able to provide samples at both time points. The first collection occurred at a median of postnatal day 6 and the second at a median of postnatal day 27.
Blood and urine samples from 2 time points were obtained from preterm infants born at <29 weeks' gestational age enrolled in the Improving Prematurity-Related Respiratory Outcomes at Vanderbilt cohort (U01 HL101456), part of the multicenter Prematurity and Respiratory Outcomes Program (PROP; U01 HL101794), a prospective, observational birth cohort of preterm infants born at <29 weeks' gestation. The infants in this study were enrolled at Vanderbilt between September 2011 and December 2013. Specimens for biomarker analysis were collected in the first month after birth with the goal of identifying mechanisms that predict pulmonary outcomes, such as bronchopulmonary dysplasia and respiratory morbidity during the first year after birth. The methods and descriptions of the PROP study have been published [20] [21] [22] [23] and are available at https://clinicaltrials.gov/ ct2/show/NCT01460576. Maternal smoking during pregnancy was assessed via standardized questionnaires and chart review, limited to "yes/no" data, without further quantification of the amount of smoking exposure.
Quantification of tocopherol isoforms was performed using gas chromatography-mass spectrometry (GC-MS). The methodology is described in detail in the Appendix (available at www.jpeds.com).
Statistical Analyses
Continuous variables were summarized using the median and 25th and 75th percentiles with interquartile range (IQR), and categorical variables were summarized using percentages. The Spearman rank correlation was used to estimate bivariate associations between all pairwise combinations of alpha-and gamma-tocopherol measured in the urine and the plasma. The Pearson test was used to test differences among categorical variables. The Wilcoxon signed-rank test for paired data was used to detect any significant change in tocopherol levels from the first to the second collection time. The Wilcoxon rank-sum test (2 groups) or the Kruskal-Wallis test (more than 2 groups) was used for comparisons across independent groups (eg, smokers vs nonsmokers). Rank methods were used to mitigate the impact of outliers and alleviate the need to consider transformations. Because we report the results of all associations tested, we did not make any formal corrections for multiple comparisons.
Results
The overall maternal and infant characteristics of our cohort with stratification by maternal smoking during pregnancy are reported in Table I . There are no significant between-group differences in any of the characteristics studied. We further stratified the same maternal and infant characteristics by maternal race, and likewise noted no significant differences between the groups (Table II; available at www.jpeds.com).
Between 1 week and 1 month after birth, the median plasma alpha-tocopherol concentration decreased in our preterm subjects from a median of 22 µmol/L (IQR, 17-28 µmol/L) to 19 µmol/L (IQR, 14-26 µmol/L) (n = 30 paired samples; P = .02, Wilcoxon signed-rank rest) and median plasma gammatocopherol concentration decreased from 6.4 µmol/L (IQR, 5.3-10.1 µmol/L) to 2.7 µmol/L (IQR, 1.9-5.0 µmol/L) (P < .001, 
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Wilcoxon signed-rank test) (Figure 1 ; available at www.jpeds.com). There were nonsignificant increases in urinary CEHC isoforms over the same time period (Table I) . At each of the 2 time points, we observed significantly lower plasma alpha-tocopherol concentrations in preterm infants of mothers who smoked (n = 15) during pregnancy compared with infants of nonsmokers (n = 26) ( Table I) . At 1 week after birth, the median alpha-tocopherol concentration was 27 µmol/L (IQR, 21-33 µmol/L) in infants of nonsmokers versus 19 µmol/L (IQR, 16-20 µmol/L) in infants of smokers (P = .007). At age 1 month, the median alphatocopherol concentration was 22 µmol/L (IQR, 15.5-28 µmol/ L) in infants of nonsmokers versus 14 µmol/L (IQR, 7-17 µmol/L) in infants of smokers (P = .002) (Figure 2 ; available at www.jpeds.com). For gamma-tocopherol, the median concentration at 1 month was 4.1 µmol/L (IQR, 2.7-8.1 µmol/L) in infants of nonsmokers versus 2.0 µmol/L (IQR, 1.7-2.7 µmol/L) in infants of smokers (P = .02). Although we observed reductions in gamma-tocopherol at 1 week and in alpha-CEHC and gamma-CEHC at both time points comparing infants of smokers and infants of nonsmokers, the differences were not statistically significant. We did not detect any difference in production of urinary F2-isoprostanes, a marker of oxidative stress, between infants of smokers and infants of nonsmokers ( Table I) . Between 1 week and 1 month after birth, we did not observe any differences in the rate of decrease in plasma-tocopherol isoforms between infants of smokers and infants of nonsmokers (P = .40 for alphatocopherol and P = .34 for gamma-tocopherol) (Figure 3 ; available at www.jpeds.com).
Although cutoffs for alpha-tocopherol deficiency are not well defined for preterm neonates, use of the current cutoff of 12.0 µmol/L for alpha-tocopherol deficiency 24 showed that 42% of the preterm infants of smokers were deficient at 1 month after birth, compared with 5% of preterm infants born to nonsmokers (P = .008).
We next examined the effect of total parenteral nutrition (TPN) on the same biomarkers at 1 month after birth, when 44% of the infants remained on TPN and the other 56% were on full enteral feeds. We noted significant increases in measured plasma alpha-tocopherol (P = .01) and gamma-tocopherol (P < .001) concentrations among those infants still on TPN (Table III ; available at www.jpeds.com).
We then stratified the relationship between tocopherol isoforms and maternal smoking by whether or not the infant remained on TPN at 1 month after birth (all infants were still on TPN at 1 week) (Figure 4 and Table IV [available at www.jpeds.com]). We found consistent decreases in the concentrations of alpha-and gamma-tocopherol for maternal smoking and increases in concentrations if TPN was present, such that infants of smokers who were no longer on TPN at 1 month had the lowest concentrations of both alphatocopherol (P < .001) and gamma-tocopherol (P < .001) and were most likely to be deficient (P = .037) ( Table IV) . Urinary F2-isoprostanes, when stratified by the presence or absence of TPN, were nonsignificantly increased in infants on TPN (P = .12) ( Table III) .
We were unable to detect significant correlations between plasma alpha-or gamma-tocopherol concentrations and their paired urinary metabolites alpha-CEHC and gamma-CEHC at either of the 2 time points. At 1 week after birth, both plasma tocopherols and their corresponding urinary metabolites were negatively correlated, and at 1 month after birth, they were positively correlated, but these effects were not significant.
Measurements of the plasma isoforms were positively and significantly correlated over time: plasma alpha-tocopherol at 1 week and 1 month (Spearman correlation coefficient, CC = 0.61; P = .003) and plasma gamma-tocopherol at 1 week and 1 month (CC = 0.46; P = .016). Meanwhile, measurements of the urinary isoforms were not correlated over time; neither urinary alpha-CEHC at 1 week and 1 month (CC = −0.26; P = .11) nor urinary gamma-CEHC at 1 week and 1 month (CC = 0.01; P = .34). We were not able to effectively stratify this analysis by TPN status due to small sample size, given that all subjects were on TPN at 1 week.
Discussion
In extremely preterm infants, plasma alpha-and gammatocopherol decline over the first month after birth regardless of maternal smoking status during pregnancy. Infants of smoking mothers who are no longer on TPN at 1 month after birth are at the greatest risk of alpha-tocopherol deficiency. The contribution of declining levels of plasma tocopherol to oxidant stress and specific health outcomes in preterm infants is unknown, and is an area worthy of study.
In preterm infants, maternal smoking during pregnancy significantly decreases plasma alpha-tocopherol, leading to higher rates of deficiency by 1 month after birth. Remaining on TPN at 1 month after birth significantly increases both plasma alphatocopherol and gamma-tocopherol concentrations. Depending on the oil source used for lipid emulsions and vitamin E in TPN, the vitamin E isoform composition may vary. For example, corn and soybean oils contain predominantly gammatocopherol, whereas sunflower and safflower oils contain predominantly alpha-tocopherol. 12 For the infants in this study, the source of lipid emulsion was IntraLipid 20%, consisting of 20% soybean oil. Gamma-tocopherol is known to have a different biological profile from alpha-tocopherol in terms of downstream oxidative and inflammatory effects, 12 and its independent associations and interactions with alpha-tocopherol on diseases of prematurity are unknown. Cook-Mills et al 14 have reported that in term neonates, increasing gamma-tocopherol concentrations were associated with reductions in forced expiratory volume in 1 second (P = .01) and forced vital capacity (P = .01), whereas increasing alpha-tocopherol was associated with increases in forced vital capacity (P = .01).
These findings in the plasma and urine of extremely preterm infants are consistent with reports that smoking decreases alphatocopherol concentrations in both pregnant mothers and their term offspring. 19, 25 The role of alpha-tocopherol in lung development and antioxidant defense is well known. The association between maternal smoking during pregnancy and THE JOURNAL OF PEDIATRICS • www.jpeds.com Volume 197 reduced alpha-tocopherol concentrations in their preterm infants points to a potentially modifiable mechanism underlying the link between maternal smoking and poor pulmonary outcomes, including bronchopulmonary dysplasia and late respiratory disease in preterm infants, 26 as has been demonstrated with vitamin C. 27 This information will be helpful in future trials of prenatal or postnatal tocopherol supplementation, as infants of smokers might be a targeted risk group for study. CEHC metabolites of tocopherol are easily transferred across the placenta, whereas alpha-and gamma-tocopherol are not as easily transferred, though they do equilibrate during pregnancy. 28, 29 Changes in infant metabolism of tocopherols over this period also may occur, given the switch in the directionality we observed in the correlations between plasma isoforms and their urinary metabolites, and future studies at age 1 month may be more fruitful.
Our study was underpowered to determine whether plasma tocopherol isoforms are correlated with their urinary metabolites and urinary F2-isoprostanes in preterm neonates. Larger, prospective studies are needed to determine whether measuring urinary metabolites reduces the need for blood draws in Figure 4 . Effects of maternal smoking and TPN on infant plasma tocopherol isoforms at 1 month after birth. Maternal smoking was noted to decrease measured concentrations of both isoforms, whereas TPN was noted to increase them. Individual data points are jittered (randomly moved up or down) along the horizontal axis so as not to overlap visually. The boxplots are (usual) Tukey boxplots. The boxes contain that 25th and 75th percentiles; the line in the middle is the median. The whiskers (lines) extend out to lesser of the most extreme value or 1.5 times the IQR. Comparisons across all groups by isoform were done via the Kruskal-Wallis test (P = .002 for alpha-tocopherol, .001 for gamma-tocopherol) Alpha-tocopherol deficiency, defined as a concentration <12.0 µmol/L, was present in 50% of infants in the mother smoker, infant off TPN group; in 25% of the infants in the mother smoker, infant on TPN group; in 10% of the mother nonsmoker, infant off TPN group; and in 0% in the mother nonsmoker, infant on TPN group (P = .037, Pearson test).
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ascertaining the tocopherol status of preterm infants, and whether urinary or plasma tocopherol levels are associated with their long-term respiratory outcomes.
Strengths of the present study include the availability of blood and urine biospecimens and a robust clinical dataset from preterm infants across time in the early postnatal period. Because all infants were treated at a single center, the TPN formulation and source were the same, as were other protocols used in treating the infants. Limitations include the small sample size and single-center study design. 30 We were not able to assess other nutritional factors, such as vitamin C or fish oilderived fatty acids, which may be relevant confounders for an oxidative effect of smoking on vitamin E. Our questionnaire data did not quantify the amount of maternal smoking exposure during pregnancy, which would be important in assessing for dose-response on infant vitamin E isoforms. Replication of our findings in a larger cohort of preterm infants will be important for future research.
Conclusions
In summary, maternal smoking decreases early-life plasma concentrations of alpha-tocopherol in their preterm infants and leads to an increased likelihood of tocopherol deficiency by 1 month of age. Infants of smokers who are no longer on TPN are at the greatest risk of deficiency. ■ 
Methods
Tocopherol Quantification for Plasma. All samples were analyzed in the Stable Isotope and Metabolomics Core Facility of the Diabetes Center at the Albert Einstein College of Medicine. For GC-MS analysis, a 30-µL plasma sample was extracted with 120 µL of methanol containing 3 internal standards: 5 nM of UC13-citrate, 5 nM tocol (a noncellular tocopherollike standard), and 1 nM of UC13_succinate. The samples were vortexed and stored at -20°C for 10 minutes. After centrifugation at 12 000 rpm for 10 minutes, 140 µL of supernatant was transferred to a sampling vial. The standard, linear curve for tocopherol analysis was prepared with concentrations of 0.1, 0.2, 0.4, 0.6, 0.8, 1, 1.25, and 1.5 nmol. The samples were dried under speed vacuum and derivatized with a 2-step derivatization procedure. First, the samples were methoximized with 50 µL of methoxyamine hydrochloride (15 mg/mL in pyridine) at 30°C for 90 minutes. The silylation step was done with 50 µL of N,O-Bis(trimethylsilyl)trifluoroacetamide (BSTFA, containing 1% TMCS) at 80 degree for 60 minutes. QC samples and NIST 1950 plasma were run for multiple times during the analysis for quality control.
The samples were then analyzed by GS-time-of-flight MS (GCT Premier; Waters, Milford, Massachusetts) for metabolic profiling and GC-MS (Agilent,) for tocopherol quantification. Profiling data were analyzed with Genedata Expressionist software (Genedata, Basel, Switzerland). Metabolite annotation was performed by comparing mass spectra and retention times with commercially available libraries, such as the Fiehn, GOLM, and NIST libraries. The MS detector was set to SIM mode with an 8.5-minute solvent delay for tocopherol quantification. The monitored ions were 460 for tocol, 502 for alpha-tocopherol, and 488 for gamma-tocopherol. Targeted (tocopherol analysis) data was analyzed with ChemStation software (Agilent).
Tocopherol Metabolite Quantification in the Urine. All samples were analyzed in the Stable Isotope and Metabolomics Core Facility, of the Diabetes Center at the Albert Einstein College of Medicine. The urine samples were thawed on ice. After centrifuge at 12 000 rpm for 10 mins, 500uL of urine was transferred to a new vial. 10 ul internal standard (0.5 mM of tocol in ethanol) and 100ul b-glucuronidase H solution (3 mg/mL in 0.1M sodium acetate solvent pH 4.5) were added to the sample. The samples were briefly vortexed and kept in 37 degree for 2 hrs. Then, 50uL 6 mol/L HCl was added to each sample. CEHC extraction was performed with 3 mL of diethylester after vortex for 30 s and centrifuge at 3000 rpm for 2 min. The supernatant was transferred to a glass vial and dried. The silylation step was done with 80 µL of BSTFA (containing 1% TMCS) at 80°C for 60 minutes. The derivatized sample was injected into GC-MS. The MS detector was set to SIM mode with an 8.5-minute solvent delay for tocopherol quantification. The monitored ions were 460 for tocol, 422 for alpha-CEHC, and 408 for gamma-CEHC. Targeted (tocopherol analysis) data was analyzed with Chemstation software.
The lower limit of detection was defined as signal-tonoise ratio (SNR) >3. SNR was calculated using Agilent MassHunter Qualitative Analysis software. The lower limit of quantification was defined as the lowest concentration with a coefficient of variation (CV; standard deviation/mean repeated injections) <20% in 6 repeated injections. CVs for different concentrations of tocopherol metabolites used for the linear standard curve (0.1 nmol [low], 0.5 nmol [medium], and 1.5 nmol [high]) were also tested with 6 repeated injections. The CVs did not change appreciably at these different concentrations (all <12%). Decreases in alpha-and gamma-tocopherol were observed in premature neonates over time, with baseline decreases in both plasma alpha-tocopherol and gamma-tocopherol in infants of smokers. However, rates of decline in alpha-and gamma-tocopherol were not influenced by maternal smoking during pregnancy (alpha-tocopherol, P = .40; gamma-tocopherol, P = .34, Wilcoxon rank-sum test). 
F2-Isoprostane
